{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fan X"],"funding":["Ministry of Science and Technology of China","National Natural Science Foundation of China"],"pagination":["218-229"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5651494"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9"],"pubmed_abstract":["In this study, chemical modification of 2'-deoxyinosine (2'-dI) and D-/L-isothymidine (D-/L-isoT) was performed on AS1411. They could promote the nucleotide-protein interaction by changing the local conformation. Twenty modified sequences were obtained, FCL-I and FCL-II showed the most noticeable activity improvement. They stabilized the G-quadruplex, remained highly resistant to serum degradation and specificity for nucleolin, further inhibited tumor cell growth, exhibited a stronger ability to influence the different phases of the tumor cell cycle, induced S-phase arrest, promoted the inhibition of DNA replication, and suppressed the unwound function of a large T antigen as powerful as AS1411. The microarray analysis and TaqMan PCR results showed that FCL-II can upregulate the expression"],"journal":["Molecular therapy. Nucleic acids"],"pubmed_title":["The Bioactivity of D-/L-Isonucleoside- and 2'-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression."],"pmcid":["PMC5651494"],"funding_grant_id":["21332010","21502104","2012CB720604","21572013"],"pubmed_authors":["Sun L","Yang X","Cai B","Yang Z","Fan X","Guan Z","Zhu Y","Zhang Y","Ma Y","Zhang L","Li K","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"The Bioactivity of D-/L-Isonucleoside- and 2'-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression.","description":"In this study, chemical modification of 2'-deoxyinosine (2'-dI) and D-/L-isothymidine (D-/L-isoT) was performed on AS1411. They could promote the nucleotide-protein interaction by changing the local conformation. Twenty modified sequences were obtained, FCL-I and FCL-II showed the most noticeable activity improvement. They stabilized the G-quadruplex, remained highly resistant to serum degradation and specificity for nucleolin, further inhibited tumor cell growth, exhibited a stronger ability to influence the different phases of the tumor cell cycle, induced S-phase arrest, promoted the inhibition of DNA replication, and suppressed the unwound function of a large T antigen as powerful as AS1411. The microarray analysis and TaqMan PCR results showed that FCL-II can upregulate the expression","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2025-04-26T09:34:26.515Z","creation":"2019-03-27T02:59:35Z"},"accession":"S-EPMC5651494","cross_references":{"pubmed":["29246300"],"doi":["10.1016/j.omtn.2017.09.010"]}}